291 related articles for article (PubMed ID: 29367723)
21. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
22. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
23. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope.
Chen S; Zheng D; Li C; Zhang W; Xu W; Liu X; Fang F; Chen Z
Biomed Res Int; 2015; 2015():901817. PubMed ID: 25767809
[TBL] [Abstract][Full Text] [Related]
24. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
[TBL] [Abstract][Full Text] [Related]
25. Novel Approaches for The Development of Live Attenuated Influenza Vaccines.
Blanco-Lobo P; Nogales A; Rodríguez L; Martínez-Sobrido L
Viruses; 2019 Feb; 11(2):. PubMed ID: 30813325
[TBL] [Abstract][Full Text] [Related]
26. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
[TBL] [Abstract][Full Text] [Related]
27. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
Tao W; Gill HS
Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219
[TBL] [Abstract][Full Text] [Related]
28. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
29. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
30. Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.
Musthaq SK; Kumar SR; Szyporta M; Kwang J
Antiviral Res; 2014 Sep; 109():42-53. PubMed ID: 24973759
[TBL] [Abstract][Full Text] [Related]
31. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.
Andrews SF; Graham BS; Mascola JR; McDermott AB
Cold Spring Harb Perspect Biol; 2018 Jul; 10(7):. PubMed ID: 28663207
[TBL] [Abstract][Full Text] [Related]
32. Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice.
Luo Y; Mohan T; Zhu W; Wang C; Deng L; Wang BZ
Sci Rep; 2018 Mar; 8(1):4577. PubMed ID: 29545521
[TBL] [Abstract][Full Text] [Related]
33. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
[TBL] [Abstract][Full Text] [Related]
34. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
35. HA2 glycopolypeptide of influenza A virus and antiviral immunity.
Varečková E; Mucha V; Kostolanský F
Acta Virol; 2013; 57(2):247-56. PubMed ID: 23600881
[TBL] [Abstract][Full Text] [Related]
36. Return of inactivated whole-virus vaccine for superior efficacy.
Furuya Y
Immunol Cell Biol; 2012 Jul; 90(6):571-8. PubMed ID: 21844883
[TBL] [Abstract][Full Text] [Related]
37. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
38. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
39. A Perspective on Nanoparticle Universal Influenza Vaccines.
Deng L; Wang BZ
ACS Infect Dis; 2018 Dec; 4(12):1656-1665. PubMed ID: 30394725
[TBL] [Abstract][Full Text] [Related]
40. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
Front Immunol; 2018; 9():2060. PubMed ID: 30271406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
